RUNX1 and chronic myelomonocytic leukemia: In contrast to the overall distinction between BPDCN and AML, we found three of these cases to exhibit synchronous concurrent manifestations of AML and/or transformed CMML with pDC features and one of these three cases even presented with genetic features typically encountered in AML with pDC-features (RUNX1 mutation; Fig. 2c, d–i).